Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML

ABSTRACT: RNA-Seq data (on MV4-11 cell line and primary AML samples), ATAC-Seq data, Source Data for the Main Figures (Figures 1-7), Source Data for the Expanded Views (EV1-5), Source Data for the Appendix Figures (Appendix Figure S1-S10).

ORGANISM(S): Homo sapiens (human) Mus musculus (mouse)

SUBMITTER:

PROVIDER: S-BSST2077 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML.

Project description: Not available

| S-EPMC12514269 | biostudies-literature

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML

Project description: Not available

| S-SCDT-10_1038-S44321-025-00296-2 | biostudies-other

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML [RNAseq_patients]

Project description:The heterogeneity of leukemic cells is the main cause of resistance to therapy in acute myeloid leukemia (AML). Consequently, innovative therapeutic approaches are critical to target a wide spectrum of leukemic clones, regardless of their genetic and non-genetic complexity. In this report, we leverage the vulnerability of AML cells to CDK6 to identify a combination therapy capable of targeting common biological processes shared by all leukemic cells, while sparing non-transformed cells. We demonstrate that the combined inhibition of CDK6 and LSD1 restores myeloid differentiation and depletes the leukemic progenitor compartment in AML samples. Mechanistically, this combination induces major changes in chromatin accessibility, leading to the transcription of differentiation genes and diminished LSC signatures. Remarkably, the combination is synergistic, induces durable changes in the cells, and is effective in PDX mouse models. While many AML samples exhibit only modest responses to LSD1 inhibition, co-targeting CDK6 restores the expected transcription response associated with LSD1 inhibition. Given the availability of clinical-grade CDK6 and LSD1 inhibitors, this combination holds significant potential for implementation in clinical settings through drug repositioning.

2025-07-16 | GSE297638 | GEO